| BDMD 0.1034 -5.22% | SOXL 54.7293 -17.92% | JDZG 0.3578 18.63% | CDT 0.0403 -20.83% | PLCE 0.3355 39.21% | SHFS 0.0289 -9.12% | KORU 8.72 -16.40% | SOXS 69.06 18.38% | NVDA 192.44 -3.84% | INTC 54.75 -6.04% | TQQQ 57.08 -8.29% | SPCX 127.855 -5.93% | RBNE 0.1371 -1.37% | U 47.8293 12.65% | IREN 19.84 -8.61% | TSLL 8.765 -15.48% | DVLT 0.0566 -17.97% | NOK 7.82 -5.33% | SQQQ 44.99 8.25% | NWGL 0.0367 -33.87% | SNAP 5.275 -10.90% | RIG 5.415 -0.64% | MUU 16.4 -14.72% | JOBY 5.32 5.35% | EOSE 1.98 -7.48% | CRWV 45.2701 -6.51% | PARA 0.1951 -38.84% | ONDS 4.905 -6.93% | XLE 64.43 1.43% | TSLA 355.68 -7.66% | AMD 439.7488 -10.03% | AMZN 267.66 0.61% | SMCI 27.79 -6.11% | GRAB 3.36 0.00% | HTZ 2.125 -5.97% | RUN 9.87 12.29% | MRVL 147.59 -7.64% | CIFR 5.94 -8.62% | XLF 59.625 0.72% | MU 736.67 -7.36% | QQQ 672.98 -2.74% | KPTI 0.0566 -22.36% | KWEB 24.78 1.89% | CRIS 1.065 -4.05% | AAPL 351.84 0.67% | STLA 4.5702 -1.72% | AMC 3.53 0.28% | PLUG 1.435 -1.71% | LABD 7.09 8.91% | OPEN 1.84 -7.07%

SMMT's Q3 Earnings Beat Estimates, Ivonescimab Development in Focus

Summit reports Q3 loss narrower than expected and posts nil sales. Ivonescimab advances through late-stage studies and new oncology collaborations.

TC Trade Conquest Newsroom November 5, 2026 ·1 min read

SMMT's Q3 Earnings Beat Estimates, Ivonescimab Development in Focus

Key takeaways

Summit reports Q3 loss narrower than expected and posts nil sales.
Ivonescimab advances through late-stage studies and new oncology collaborations.
Stock in this story: SMMT. See its latest quote and chart on Trade Conquest.

Summit reports Q3 loss narrower than expected and posts nil sales. Ivonescimab advances through late-stage studies and new oncology collaborations.

See the latest quote, chart and news for SMMT.

Read the full story at zacks.com ↗

Want trade ideas like this in real time? Subscribe to Trade Conquest.

More news